Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sohini Mondal

Are Wall Street Analysts Predicting DexCom Stock Will Climb or Sink?

Valued at a market cap of $29.6 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company specializing in designing, developing, and commercializing continuous glucose monitoring (CGM) systems. Its products, including the Dexcom G6 and G7, aim to help people with diabetes manage their blood glucose levels through real-time data transmission and monitoring.

Shares of the medical device company have underperformed the broader market over the past 52 weeks. DXCM has declined 27.9% over this time frame, while the broader S&P 500 Index ($SPX) has gained 30.4%. In 2024, DXCM stock dropped nearly 39%, compared to SPX's 23.1% YTD gain.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.